From GlobeNewswire: 2025-02-07 16:58:09

Pliant Therapeutics, Inc. has paused enrollment and dosing in the BEACON-IPF Phase 2b trial for idiopathic pulmonary fibrosis following a DSMB recommendation. Data is being reviewed while current patients are monitored, with blinding maintained for trial integrity. The company is informing regulatory authorities and investigators involved in the trial. Pliant Therapeutics specializes in developing treatments for fibrotic diseases, with lead product candidate bexotegrast in development for IPF. The company has received designations from the FDA and European Medicines Agency for bexotegrast in IPF, and has initiated a Phase 2b/3 trial. Additional clinical programs are also in progress.



Read more at GlobeNewswire: Pliant Therapeutics Provides Update on BEACON-IPF, a Phase